Using artificial pancreas technology to improve heart health in type 1 diabetes
Using Closed-Loop Artificial Pancreas Technology to Reduce Glycemic Variability and Subsequently Improve Cardiovascular Health in Type 1 Diabetes
This study tests if using artificial pancreas technology can help people with type 1 diabetes improve their heart health by better controlling their blood sugar levels.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years to 40 Years |
| Sex | All |
| Sponsor | University of Virginia Academic / other |
| Locations | 1 site (Charlottesville, Virginia) |
| Trial ID | NCT05653518 on ClinicalTrials.gov |
What this trial studies
This study investigates the cardiovascular effects of artificial pancreas (AP) technology in individuals with type 1 diabetes. The AP system, which includes an insulin pump and a continuous glucose monitor (CGM), aims to mimic the natural glucose-regulating function of a healthy pancreas. Participants will be randomly assigned to either receive AP technology or continue with their current diabetes management for 12 weeks. The study will assess whether better blood glucose control can lead to reduced inflammation and improved cardiovascular function.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 to 40 with a clinical diagnosis of type 1 diabetes for at least one year and specific health metrics.
Not a fit: Patients outside the age range, those with uncontrolled blood glucose levels, or who are pregnant may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly enhance cardiovascular health in patients with type 1 diabetes.
How similar studies have performed: Other studies have shown promising results with artificial pancreas technology, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Clinical diagnosis, based on World Health Organization criteria, of type 1 diabetes for at least one year 2. Currently using insulin for at least six months 3. Ages 18-≤40 years 4. Hemoglobin A1c \<10.5% 5. Body mass index 18-30 kg/m2 6. Blood pressure \<140/90 mmHg 7. For females, not currently known to be pregnant or breastfeeding 8. If female and sexually active, must agree to use a form of contraception to prevent pregnancy while a participant in the study. A negative serum or urine pregnancy test will be required for all females of childbearing potential. Participants who become pregnant will be discontinued from the study. Also, participants who during the study develop and express the intention to become pregnant within the timespan of the study will be discontinued 9. Both pump and MDI users will use insulin parameters such as carbohydrate ratio and correction factors consistently in order to dose insulin for meals or corrections; pump users will have history of entering this information into their pump 10. Willingness to suspend use of any personal CGM for the duration of the clinical trial once the study CGM is in use 11. Access to internet and willingness to upload data during the study as needed, including data generated prior to the start of the study 12. Current use of a glucometer that is downloadable; or willingness to use a study glucometer 13. Investigator has confidence that the participant can successfully operate all study devices and is capable of adhering to the protocol 14. Willingness to use personal lispro (Humalog) or aspart (Novolog) and to use no other insulin besides lispro (Humalog) or aspart (Novolog) during the study 15. Total daily insulin dose (TDD) at least 10 U/day. 16. Willingness not to start any new non-insulin glucose-lowering agent during the trial Exclusion Criteria: 1. Severe hypoglycemia resulting in seizure or loss of consciousness in the 12 months prior to enrollment 2. Diagnosis of diabetic ketoacidosis in the 12 months prior to enrollment 3. Prior diagnosis of cardiac disease (e.g., myocardial infarction, congestive heart failure) 4. Cerebrovascular accident in the 12 months prior to enrollment 5. Uncontrolled resting arterial hypertension 6. Conditions that would make use of a CGM difficult (e.g., blindness, severe arthritis, immobility) 7. Current use of oral/inhaled glucocorticoids or other medications, which in the judgment of the investigator would be a contraindication to participation in the study 8. Concurrent use of any non-insulin glucose-lowering agent (including metformin, GLP-1 agonists, pramlintide, DPP-4 inhibitors, SGLT-2 inhibitors, and/or sulfonylureas) 9. Hemophilia or any other bleeding disorder 10. Currently being treated for a seizure disorder 11. A medical condition or medication, which in the opinion of the investigator or designee, would put the participant or study at risk 12. Current smokers or those who have quit smoking \<2 years ago 13. Screening Electrocardiogram (ECG) findings indicative of arrhythmia, sinus node disease, or ischemic heart disease 14. Any woman with hemoglobin (Hgb) \<11 g/dL or any man with Hgb \<12 g/dL on screening laboratory evaluation (i.e., complete blood count) 15. History of hypersensitivity or prior adverse reaction (e.g., anaphylaxis or angioedema) to IV regular insulin infusion 16. Diagnosis of peripheral neuropathy (assessed by monofilament examination), macroalbuminuria (urine albumin:creatinine \>300 mg per g), or retinopathy beyond mild, nonproliferative retinopathy 17. Unstable (i.e., dose adjustment less than 4 weeks prior to study enrollment) doses of vasoactive medications (e.g., calcium channel blockers, statins, nitrates, alpha-blockers, beta-blockers, ACE inhibitors, etc.) 18. History of hypersensitivity or prior adverse reaction to Definity microbubble infusion 19. Current enrollment in another clinical trial, unless approved by the investigator of both studies or if clinical trial is a non-interventional registry trial
Where this trial is running
Charlottesville, Virginia
- University of Virginia Health System — Charlottesville, Virginia, United States (Recruiting)
Study contacts
- Principal investigator: William B Horton, MD — University of Virginia
- Study coordinator: William B Horton, MD
- Email: WBH2N@uvahealth.org
- Phone: 434-924-1828
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.